Latest news with #CogstateLimited
Yahoo
09-04-2025
- Business
- Yahoo
One Cogstate Insider Raised Their Stake In The Previous Year
From what we can see, insiders were net buyers in Cogstate Limited's (ASX:CGS ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. The Non-Executive Chairman Martyn Myer made the biggest insider purchase in the last 12 months. That single transaction was for AU$108k worth of shares at a price of AU$1.08 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of AU$1.27. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction! See our latest analysis for Cogstate Cogstate is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Insiders own 37% of Cogstate shares, worth about AU$81m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. It doesn't really mean much that no insider has traded Cogstate shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. Overall we don't see anything to make us think Cogstate insiders are doubting the company, and they do own shares. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Cogstate . If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
ASX Penny Stocks To Watch Under A$200M Market Cap
After a turbulent Week 10, the Australian share market is poised for a rebound, with the ASX 200 expected to climb back over 8,000 points. In such fluctuating conditions, identifying stocks with strong financial foundations becomes crucial. While 'penny stocks' may seem like an outdated term, they still hold potential for growth and value discovery in smaller or newer companies. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.73 A$81.61M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.22 A$152.79M ★★★★★★ GTN (ASX:GTN) A$0.55 A$108.01M ★★★★★★ Regal Partners (ASX:RPL) A$3.09 A$1.04B ★★★★★★ IVE Group (ASX:IGL) A$2.35 A$363.99M ★★★★★☆ CTI Logistics (ASX:CLX) A$1.74 A$135.74M ★★★★☆☆ West African Resources (ASX:WAF) A$2.21 A$2.52B ★★★★★★ GR Engineering Services (ASX:GNG) A$2.79 A$466.46M ★★★★★★ SHAPE Australia (ASX:SHA) A$2.91 A$240.77M ★★★★★★ Accent Group (ASX:AX1) A$1.86 A$1.05B ★★★★☆☆ Click here to see the full list of 1,011 stocks from our ASX Penny Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Alkane Resources Ltd is an Australian company focused on gold exploration and production, with a market capitalization of A$381.49 million. Operations: The company generated revenue of A$206.19 million from its gold operations. Market Cap: A$381.49M Alkane Resources, with a market cap of A$381.49 million, focuses on gold exploration and production. Recent earnings for the half year ended December 2024 show sales of A$121.5 million and net income of A$13.16 million, indicating growth compared to the previous year. Despite no debt concerns and seasoned management, challenges include lower profit margins (9% vs 16.2% last year) and insufficient short-term assets to cover liabilities (A$64.1M vs A$71.1M). The company's stock trades significantly below its estimated fair value, offering potential upside if operational improvements continue alongside forecasted earnings growth of 53.39% per year. Click to explore a detailed breakdown of our findings in Alkane Resources' financial health report. Explore Alkane Resources' analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Cogstate Limited is a neuroscience technology company focused on developing and commercializing digital brain health assessments for academic and industry research, with a market cap of A$237.25 million. Operations: Cogstate generates revenue from two main segments: Healthcare (including Sport) contributing $2.98 million and Clinical Trials (including Precision Recruitment Tool & Research) accounting for $44.22 million. Market Cap: A$237.25M Cogstate Limited, with a market cap of A$237.25 million, has demonstrated robust financial performance in recent periods. For the half year ended December 2024, Cogstate reported revenue of US$23.94 million and net income of US$3.9 million, reflecting growth from the previous year. The company benefits from being debt-free and maintains strong liquidity with short-term assets significantly exceeding liabilities (US$46.9M vs US$12.6M). Its earnings growth rate surpasses industry averages, supported by stable volatility and experienced management and board teams. Trading at a favorable price-to-earnings ratio compared to peers suggests potential value for investors seeking exposure in this segment. Click here and access our complete financial health analysis report to understand the dynamics of Cogstate. Review our growth performance report to gain insights into Cogstate's future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Metals X Limited is an Australian company focused on the production of tin, with a market capitalization of A$474.22 million. Operations: The company's revenue is primarily derived from its 50% interest in the Renison Tin Operation, contributing A$218.82 million. Market Cap: A$474.22M Metals X Limited, with a market cap of A$474.22 million, has shown significant financial improvement, reporting net income of A$102.35 million for 2024 compared to A$14.59 million the previous year. The company benefits from strong financial health, with cash exceeding total debt and short-term assets covering both short and long-term liabilities comfortably. Despite a slight decrease in the Renison Tin Operation's reserve grade and contained tin over the past year, Metals X maintains a robust mine life estimate of approximately 10 years. Earnings growth far outpaces industry averages, though recent results include notable one-off gains impacting reported figures. Jump into the full analysis health report here for a deeper understanding of Metals X. Assess Metals X's previous results with our detailed historical performance reports. Discover the full array of 1,011 ASX Penny Stocks right here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ALK ASX:CGS and ASX:MLX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
21-02-2025
- Business
- Yahoo
Cogstate Limited Just Recorded A 9.5% Revenue Beat: Here's What Analysts Think
Shareholders of Cogstate Limited (ASX:CGS) will be pleased this week, given that the stock price is up 19% to AU$1.40 following its latest half-yearly results. Results overall were respectable, with statutory earnings of US$0.031 per share roughly in line with what the analyst had forecast. Revenues of US$23m came in 9.5% ahead of analyst predictions. The analyst typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimate suggests is in store for next year. Check out our latest analysis for Cogstate Taking into account the latest results, Cogstate's sole analyst currently expect revenues in 2025 to be US$47.7m, approximately in line with the last 12 months. Statutory earnings per share are expected to dip 7.9% to US$0.039 in the same period. Before this earnings report, the analyst had been forecasting revenues of US$45.0m and earnings per share (EPS) of US$0.028 in 2025. There's been a pretty noticeable increase in sentiment, with the analyst upgrading revenues and making a very substantial lift in earnings per share in particular. Despite these upgrades,the analyst has not made any major changes to their price target of AU$1.50, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Cogstate's revenue growth is expected to slow, with the forecast 1.9% annualised growth rate until the end of 2025 being well below the historical 13% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 23% per year. Factoring in the forecast slowdown in growth, it seems obvious that Cogstate is also expected to grow slower than other industry participants. The most important thing here is that the analyst upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Cogstate following these results. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have analyst estimates for Cogstate going out as far as 2027, and you can see them free on our platform here. Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
